MA44489A - Pyrimidines et variants de celles-ci, et leurs utilisations - Google Patents
Pyrimidines et variants de celles-ci, et leurs utilisationsInfo
- Publication number
- MA44489A MA44489A MA044489A MA44489A MA44489A MA 44489 A MA44489 A MA 44489A MA 044489 A MA044489 A MA 044489A MA 44489 A MA44489 A MA 44489A MA 44489 A MA44489 A MA 44489A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrimidins
- variants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662313334P | 2016-03-25 | 2016-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44489A true MA44489A (fr) | 2019-01-30 |
Family
ID=59900805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044489A MA44489A (fr) | 2016-03-25 | 2017-03-20 | Pyrimidines et variants de celles-ci, et leurs utilisations |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10662162B2 (fr) |
| EP (1) | EP3433258B1 (fr) |
| JP (1) | JP6902045B2 (fr) |
| KR (1) | KR102377805B1 (fr) |
| CN (1) | CN108779119B (fr) |
| AU (1) | AU2017237929B2 (fr) |
| CA (1) | CA3018180C (fr) |
| MA (1) | MA44489A (fr) |
| MX (1) | MX384368B (fr) |
| RU (1) | RU2760733C2 (fr) |
| WO (1) | WO2017165255A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3016773A1 (fr) | 2016-03-14 | 2017-09-21 | Ronald Charles Hawley | Pyrimidines et variantes de celles-ci, et leurs utilisations |
| JP6902045B2 (ja) | 2016-03-25 | 2021-07-14 | アファレント ファーマシューティカルズ インコーポレイテッド | ピリミジンおよびそのバリアント、ならびにそのための使用 |
| DK3555048T3 (da) | 2016-12-19 | 2021-10-11 | Novartis Ag | Nye picolinsyrederivater og deres anvendelse som mellemprodukter |
| BR112019012340B1 (pt) * | 2016-12-20 | 2022-01-11 | Afferent Pharmaceuticals, Inc. | Forma a de citrato cristalino de 5-(2,4-diamino-pirimidin-5-iloxi)-4-isopropil-2-metoxibenzenossulfonamida, bem como sua composição farmacêutica e usos |
| EP3712144B1 (fr) * | 2017-11-01 | 2024-02-14 | Beijing Tide Pharmaceutical Co., Ltd. | Antagoniste du récepteur p2x3 et/ou p2x2/3, composition pharmaceutique le comprenant et son utilisation |
| CN107778255B (zh) * | 2017-11-16 | 2019-10-25 | 山东大学 | 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 |
| AU2020265969A1 (en) * | 2019-04-30 | 2021-12-16 | Beijing Tide Pharmaceutical Co., Ltd. | Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof |
| WO2020221277A1 (fr) * | 2019-04-30 | 2020-11-05 | 北京泰德制药股份有限公司 | Procédé de traitement de la douleur associée à l'endométriose à l'aide d'un composé de diaminopyrimidine |
| CA3138780A1 (fr) * | 2019-04-30 | 2020-11-05 | Beijing Tide Pharmaceutical Co., Ltd. | Methode de traitement de la toux a l'aide d'un compose de diaminopyrimidine |
| WO2020244607A1 (fr) * | 2019-06-06 | 2020-12-10 | 北京泰德制药股份有限公司 | Antagoniste du récepteur p2x3 et/ou p2x2/3, composition pharmaceutique le contenant et son utilisation |
| CN120058573A (zh) * | 2025-04-29 | 2025-05-30 | 潍坊学院 | 一种1-三溴甲基磺酰基萘及其衍生物的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2953567A (en) * | 1956-11-23 | 1960-09-20 | Burroughs Wellcome Co | 5-phenylmercaptopyrimidines and method |
| EP1165522A1 (fr) * | 1999-04-06 | 2002-01-02 | Krenitsky Pharmaceuticals, Inc. | Thiopyrimidines neurotrophiques substitues |
| ES2272567T3 (es) | 2000-12-21 | 2007-05-01 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de proteina quinasas. |
| CN1930135B (zh) * | 2004-03-05 | 2011-12-28 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3拮抗剂的二氨基嘧啶 |
| BRPI0615613A2 (pt) * | 2005-09-01 | 2009-05-19 | Hoffmann La Roche | diaminopirimidinas como moduladores de p2x3 e p3x2/3 |
| ES2562056T3 (es) | 2005-09-01 | 2016-03-02 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores P2X3 y P2X2/3 |
| CA2619919C (fr) * | 2005-09-01 | 2014-04-01 | F. Hoffmann-La Roche Ag | Diaminopyrimidines en tant que modulateurs de p2x3 et p2x2/3 |
| CA2620034C (fr) * | 2005-09-01 | 2013-10-01 | F. Hoffmann-La Roche Ag | Diaminopyrimidines comme modulateurs p2x3 et p2x2/3 |
| CN101522641B (zh) * | 2006-10-04 | 2012-07-04 | 弗·哈夫曼-拉罗切有限公司 | 合成苯氧基二氨基嘧啶衍生物的方法 |
| WO2008104474A1 (fr) | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| WO2008104472A1 (fr) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Dérivés de 2, 4 -diaminopyrimidine et utilisation de ces derniers comme antagonistes p2x ou comme promédicaments de ceux-ci |
| CN101842359A (zh) * | 2007-10-31 | 2010-09-22 | 日产化学工业株式会社 | 哒嗪酮化合物和p2x7受体抑制剂 |
| GB2471713A (en) * | 2009-07-08 | 2011-01-12 | Univ Greenwich | 1,2,4-triazine derivatives and their use as sodium channel blockers |
| TWI637949B (zh) * | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| WO2015027212A1 (fr) * | 2013-08-23 | 2015-02-26 | Afferent Pharmaceuticals Inc. | Diaminopyrimidines en tant que modulateurs des récepteurs p2x3 et p2x 2/3 pour le traitement de la toux aiguë, subaiguë ou chronique |
| EP3981406A1 (fr) * | 2014-07-03 | 2022-04-13 | Afferent Pharmaceuticals Inc. | Procédés et compositions pour traiter les maladies et les affections |
| CA3016773A1 (fr) * | 2016-03-14 | 2017-09-21 | Ronald Charles Hawley | Pyrimidines et variantes de celles-ci, et leurs utilisations |
| JP6902045B2 (ja) * | 2016-03-25 | 2021-07-14 | アファレント ファーマシューティカルズ インコーポレイテッド | ピリミジンおよびそのバリアント、ならびにそのための使用 |
-
2017
- 2017-03-20 JP JP2018549444A patent/JP6902045B2/ja active Active
- 2017-03-20 MX MX2018011622A patent/MX384368B/es unknown
- 2017-03-20 US US16/080,840 patent/US10662162B2/en active Active
- 2017-03-20 CA CA3018180A patent/CA3018180C/fr active Active
- 2017-03-20 MA MA044489A patent/MA44489A/fr unknown
- 2017-03-20 AU AU2017237929A patent/AU2017237929B2/en active Active
- 2017-03-20 CN CN201780019534.0A patent/CN108779119B/zh active Active
- 2017-03-20 EP EP17770880.7A patent/EP3433258B1/fr active Active
- 2017-03-20 RU RU2018137032A patent/RU2760733C2/ru active
- 2017-03-20 KR KR1020187029805A patent/KR102377805B1/ko active Active
- 2017-03-20 WO PCT/US2017/023126 patent/WO2017165255A1/fr active Application Filing
-
2020
- 2020-04-13 US US16/846,452 patent/US11230532B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200239421A1 (en) | 2020-07-30 |
| WO2017165255A1 (fr) | 2017-09-28 |
| US20190055202A1 (en) | 2019-02-21 |
| EP3433258B1 (fr) | 2023-07-19 |
| JP6902045B2 (ja) | 2021-07-14 |
| MX384368B (es) | 2025-03-14 |
| EP3433258A1 (fr) | 2019-01-30 |
| AU2017237929B2 (en) | 2021-04-15 |
| KR102377805B1 (ko) | 2022-03-22 |
| BR112018069105A2 (pt) | 2019-01-29 |
| AU2017237929A1 (en) | 2018-09-13 |
| RU2018137032A (ru) | 2020-04-27 |
| US10662162B2 (en) | 2020-05-26 |
| JP2019510025A (ja) | 2019-04-11 |
| CN108779119A (zh) | 2018-11-09 |
| US11230532B2 (en) | 2022-01-25 |
| EP3433258A4 (fr) | 2019-10-30 |
| RU2018137032A3 (fr) | 2020-05-22 |
| CA3018180C (fr) | 2024-02-20 |
| RU2760733C2 (ru) | 2021-11-30 |
| CA3018180A1 (fr) | 2017-09-28 |
| KR20180128015A (ko) | 2018-11-30 |
| MX2018011622A (es) | 2019-03-28 |
| CN108779119B (zh) | 2022-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43821A (fr) | Pyrimidines et variantes de celles-ci, et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| MA44489A (fr) | Pyrimidines et variants de celles-ci, et leurs utilisations | |
| EP3490565A4 (fr) | Modulateurs de récepteurs de chimiokine et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| EP3471727A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3472129A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3389658A4 (fr) | Inhibiteurs de glycosidase et leurs utilisations | |
| EP3538261A4 (fr) | Catalyseurs en pérovskite et leurs utilisations | |
| EP3328199A4 (fr) | Compositions antimicrobiennes et leurs utilisations | |
| EP3344624A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| EP3337486A4 (fr) | Composés deutérés et leurs utilisations | |
| EP3313530A4 (fr) | Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci | |
| EP3349802A4 (fr) | Dendrimères lipocationiques et leurs utilisations | |
| EP3283517A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| EP3334500A4 (fr) | Conjugués de médicament multi-ligands et leurs utilisations | |
| EP3471726A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3341007A4 (fr) | Inhibiteurs de malt1 et leurs utilisations | |
| MA46901A (fr) | Agents psychotropes et leurs utilisations | |
| MA46945A (fr) | Exopolysaccharides et leurs utilisations | |
| EP3450444A4 (fr) | Composés de type crocine et utilisations correspondantes | |
| MA41495A (fr) | Composés benzoxaborole et leurs utilisations | |
| EP3445768A4 (fr) | Inhibiteurs de erbb et leurs utilisations |